Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 09, 2016 11:40 AM ET

Pharmaceuticals

Company Overview of F. Hoffmann-La Roche Ltd

Company Overview

F. Hoffmann-La Roche Ltd. provides in-vitro diagnostics and drugs for cancer and transplantation. The company specializes in medicines for oncology, virology, inflammation, metabolism, CNS, clinical chemistry, immunology, urinalysis, blood screening, genetics, infectious diseases, and microbiology. Its products include cancer treatments, such as Avastin, Herceptin, and MabThera that are also effective in the treatment of rheumatoid arthritis, anemia, and osteoporosis. The company also researches, develops, and produces molecular diagnostic reagents, test systems, and test kits. In addition, it provides automated instruments, software, consumables, and IT solutions used in in-vitro diagnostic...

Konzern-Hauptsitz

Grenzacherstrasse 124

Basel,  4070

Switzerland

Founded in 1896

Phone:

41 61 688 11 11

Fax:

41 61 691 93 91

Key Executives for F. Hoffmann-La Roche Ltd

Chief Executive Officer of Roche Group
Age: 48
Head of Roche Basel Site
Compensation as of Fiscal Year 2015.

F. Hoffmann-La Roche Ltd Key Developments

F. Hoffmann-La Roche AG Reports Earnings Results for the Year Ended December 31, 2015

F. Hoffmann-La Roche AG reported earnings results for the year ended December 31, 2015. For the period the company announced net income attributable to shareholders was CHF 8.86 billion, or CHF 10.28 per diluted share, compared to CHF 9.33 billion, or CHF 10.81 per diluted share, for the year ended December 31, 2014. Sales was CHF 48.14 billion, compared to CHF 47.46 billion for the year ended December 31, 2014. Operating profit was CHF 13.82 billion, compared to CHF 14.09 billion for the year ended December 31, 2014. Profit before taxes was CHF 11.99 billion, compared to CHF 12.51 billion for the year ended December 31, 2014.

F Hoffmann-La Roche and Glenmark Pharmaceuticals Settle Patent Litigation on Cancer Therapy

F Hoffmann-La Roche and Glenmark Pharmaceuticals have settled a patent litigation on lung cancer therapy erlotinib hydrochloride out of court. Roche received the patent in India for erlotinib hydrochloride, which is sold under the brand name 'Tarceva', on February 23, 2007. But the drug maker got engaged in patent disputes with Cipla over Tarceva. Glenmark and Roche ensured that they had reached an agreement over existing patent disputes related to the anti-cancer drug Erlotinib Hydrochloride, according to a joint statement by the two companies. As part of the contract, the companies had ceased all significant patent litigation on that product and Glenmark had approved the patent rights of the Swiss company. Tarceva is developed and commercialized by Astellas Pharma US in collaboration with Genetech, Chugai and Roche in the United States, Japan and rest of the world, respectively.

F. Hoffmann-La Roche Ltd Presents at 8th Annual Biotech Showcase Investor Conference 2016, Jan-12-2016 08:00 AM

F. Hoffmann-La Roche Ltd Presents at 8th Annual Biotech Showcase Investor Conference 2016, Jan-12-2016 08:00 AM. Venue: Parc 55 San Francisco, 55 Cyril Magnin Street, San Francisco, CA 94102, United States. Speakers: Simon Meier, Investment Director.

Similar Private Companies By Industry

Company Name Region
Daiichi Sankyo (Schweiz) AG Europe
Baxalta GmbH Europe
MSD Merck Sharp & Dohme A.G. Europe
TRIN Pharma GmbH Europe
Ixodes AG Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact F. Hoffmann-La Roche Ltd, please visit www.roche.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.